Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)
Launched by FEDERICO II UNIVERSITY · Dec 6, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) is a clinical trial aimed at understanding how patients with serious heart conditions, such as acute coronary syndrome, heart failure, and cardiogenic shock, are treated and what outcomes they experience. The study is currently recruiting participants who are 18 years or older and have been admitted to the intensive cardiac care unit (ICCU) for acute cardiovascular diseases. To join the study, patients must give their written consent for their health information to be collected.
Participants in this trial can expect to help researchers gather important data about the current practices in managing these heart conditions. This information will help improve care for future patients with similar issues. It's important to note that patients who choose not to provide consent for data collection will not be eligible to participate. Overall, this study aims to enhance our understanding of acute cardiovascular diseases and the effectiveness of various treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Acute cardiovascular disease admitted at our ICCU
- • 2. Age ≥18 years;
- • 3. Written informed consent.
- Exclusion Criteria:
- • 1) Patients not providing consent to data collection
About Federico Ii University
Federico II University, located in Naples, Italy, is a prestigious academic institution with a strong emphasis on advanced research and clinical innovation. As a clinical trial sponsor, the university is committed to fostering the development of novel therapeutic interventions and enhancing patient care through rigorous scientific inquiry. With a multidisciplinary approach, Federico II University collaborates with healthcare professionals, researchers, and industry partners to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Its dedication to improving health outcomes is reflected in its robust research programs and commitment to translating scientific findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Napoli, , Italy
Patients applied
Trial Officials
Giuseppe Gargiulo, MD, PhD
Principal Investigator
Department of Advanced Biomedical Sciences
Giovanni Esposito, MD, PhD
Study Chair
Department of Advanced Biomedical Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported